Jon W. Osgood

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

Cutlass Capital LLC (Cutlass Capital) is a venture capital firm founded in 2001 by Jon Osgood and David Hetz. The firm is headquartered in Boston.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

Cutlass Capital LLC (Cutlass Capital) is a venture capital firm founded in 2001 by Jon Osgood and David Hetz. The firm is headquartered in Boston.

Cutlass Capital LLC (Cutlass Capital) is a venture capital firm founded in 2001 by Jon Osgood and David Hetz. The firm is headquartered in Boston.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

Cutlass Capital LLC (Cutlass Capital) is a venture capital firm founded in 2001 by Jon Osgood and David Hetz. The firm is headquartered in Boston.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cutlass Capital LLC (Cutlass Capital) is a venture capital firm founded in 2001 by Jon Osgood and David Hetz. The firm is headquartered in Boston.

Cutlass Capital LLC (Cutlass Capital) is a venture capital firm founded in 2001 by Jon Osgood and David Hetz. The firm is headquartered in Boston.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cutlass Capital LLC (Cutlass Capital) is a venture capital firm founded in 2001 by Jon Osgood and David Hetz. The firm is headquartered in Boston.

Cutlass Capital LLC (Cutlass Capital) is a venture capital firm founded in 2001 by Jon Osgood and David Hetz. The firm is headquartered in Boston.

TranS1, Inc. designs and develops surgical procedures and equipment for back pain. It is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single-level and two-level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. Its primary technology is AxiaLIF, a minimally invasive access and fusion system that enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. The company specializes in bringing innovative spine solutions to market, including AxiaLIF and AxiaLIF 2L+, technologies that allow surgeons to perform lower lumbar fusions that result in high fusion rates and low complication rates. The company is also developing a motion preservation platform to be delivered through this minimally invasive, trans-sacral approach. TranS1 was founded in May 2000 and is headquartered in Wilmington, NC.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.

Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY.